Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer.

Saved in:
Bibliographic Details
Title: Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer.
Authors: Wakatsuki T; Department of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan. takeru.wakatsuki@jfcr.or.jp., Yamamoto N; Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan., Ishizuka N; Center for Digital Transformation of Healthcare Graduate School of Medicine, Kyoto University, Kyoto, Japan., Hironaka S; Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan., Minashi K; Clinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan., Kadowaki S; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan., Hirano H; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Shoji H; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Yamaguchi T; Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan., Chin K; Department of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan., Ogura M; Department of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan., Nakayama I; Department of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Osumi H; Department of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan., Ueki A; Department of Clinical Genetic Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Kitano S; Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.; Division of Clinical Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan., Boku N; Department of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan., Yamaguchi K; Department of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan., Takahari D; Department of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.; Department of Medical Oncology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Source: Targeted oncology [Target Oncol] 2026 Mar; Vol. 21 (2), pp. 269-283. Date of Electronic Publication: 2026 Mar 15.
Publication Type: Journal Article
Journal Info: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1776-260X
DOI:10.1007/s11523-026-01204-5